The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.
Department of Radiology, University of Utah, Salt Lake City, UT 84102, USA. firstname.lastname@example.org
Neuroscience letters 2006;406(3):189-93.
Accumulating evidence suggests that oxidative stress may be a major etiologic factor in initiating and promoting neurodegeneration in Alzheimer disease. Contributing to this, there is a dyshomeostasis of metal ions in Alzheimer disease with abnormally high levels of redox-active metals, particularly iron, in affected areas of the brain. Although it is unclear whether metal excesses are the sole cause of oxidative stress and neurodegeneration or a by-product of neuronal loss, the finding that metal chelators can partially solubilize amyloid-beta deposits in Alzheimer disease suggests a promising therapeutic role for chelating agents. However, the blood-brain barrier and toxicity of known chelators limit their utility. In this study, we suggest that covalent conjugation of iron chelators with nanoparticles may help overcome the limitations in blood-brain barrier permeability of existing chelation therapy. Using in vitro studies, we have shown that a chelator-nanoparticle system and the chelator-nanoparticle system complexed with iron, when incubated with human plasma, preferentially adsorb apolipoprotein E and apolipoprotein A-I, that would facilitate transport into and out of the brain via mechanisms used for transporting low-density lipoprotein. Our studies suggest a unique approach, utilizing nanoparticles, to transport chelators and chelator-metal complexes in both directions across the blood-brain barrier, thus providing safer and more effective chelation treatment in Alzheimer disease and other neurodegenerative diseases.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Mayeux, Richard P
1 December 1998 - 31 January 2004
NATIONAL INSTITUTE ON AGING
Total Funding: $ 5,549,515
Smith, Mark A
1 May 1999 - 30 April 2006
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Total Funding: $ 750,386
Breitner, John C
30 September 1994 - 28 February 2002
NATIONAL INSTITUTE ON AGING
Total Funding: $ 9,374,878
Gang Liu; Ping Men; Wataru Kudo; George Perry; Mark A SmithNeuroscience letters 2009;455(3):187-90.
Gang Liu; Ping Men; George Perry; Mark A SmithMethods in molecular biology (Clifton, N.J.) 2010;610():123-44.
Gang Liu; Ping Men; George Perry; Mark A SmithProgress in brain research 2009;180():97-108.
Appears in this Publication
Author of this Publication